High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy-Reference-Cited by-全球学者库

High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy

Published:2009-11 Issue:8 Volume:30 Page:437-447
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Min Ye,Qiang Fu,Peng Li,Zhu Zhu

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference30 articles.

1. Treatment of acute lymphoblastic leukemia;Pui;N Engl J Med,2006

2. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?;Mantadakis;Pharmocotherapy,2005

3. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma;Widemann;Cancer,2004

4. Severe complications after high-dose methotrexate treatment;Takami;Acta Oncol,1995

5. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy;Hornung;J Rheumatol,2008

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy;British Journal of Clinical Pharmacology;2023-12-13

2. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review;European Journal of Clinical Pharmacology;2023-11-07

3. A semimechanistic pharmacokinetic/pharmacodynamic model for alanine aminotransferase‐based hepatotoxicity of methotrexate in paediatric patients with acute lymphoid leukaemia;British Journal of Clinical Pharmacology;2023-08-21

4. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients;European Journal of Pharmaceutical Sciences;2023-07

5. Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma;Pediatric Hematology and Oncology;2023-05-17